著者

Takumi Imai Takayuki Hosoi Hiroshi Hagino Takanori Yamamoto Tatsuhiko Kuroda Hiroshi Watanabe Shiro Tanaka

出版者

Japan Epidemiological Association

雑誌

Journal of Epidemiology (ISSN:09175040)

巻号頁・発行日

pp.JE20220099, (Released:2022-12-24)

参考文献数

22

被引用文献数

2

---

ObjectiveThis study aimed to estimate incidence rates of femoral shaft fracture in patients who were treated with antiresorptive drugs.DesignCohort studyMethodsWe used data from the National Database of Health Insurance Claims of Japan from April 2009 and October 2016. All patients with new use of an antiresorptive drug, prescription-free period of ≥3 months, and no prior femoral fractures were included. Femoral shaft fractures were identified using a validated definition based on ICD-10 codes. Incidence rate ratios were estimated using Poisson regression with adjustment for sex, age, and the Charlson Comorbidity Index.ResultsWe identified 7,958,655 patients (women, 88.4%; age ≥75 years, 51.2%). Femoral shaft fractures were identified in 22,604 patients. Incidence rates per 100,000 person-years was 74.8 for women, 30.1 for men, 30.1 for patients aged ≤64 years, 47.7 for patients aged 65–74 years, and 99.0 for patients aged ≥75 years. Adjusted incidence rate ratios in patients taking versus not taking each type of antiresorptive drug were 1.00 (95% confidence interval (CI), 0.98–1.03) for bisphosphonates, 0.46 (95% CI, 0.44–0.48) for selective estrogen receptor modulators, 0.24 (95% CI, 0.18–0.32) for estrogens, 0.75 (95% CI, 0.71–0.79) for calcitonins, and 0.93 (95% CI, 0.84–1.03) for denosumab. The adjusted incidence rate ratio for alendronate was 1.18 (95% CI, 1.14–1.22).ConclusionsThe incidence rates of femoral shaft fracture varied across patients treated with different antiresorptive drugs. Further research on a specific antiresorptive drug can increase understanding of the risk of femoral shaft fracture

著者

Natsuko SOGABE Rieko MARUYAMA Takayuki HOSOI Masae GOSEKI-SONE

出版者

Center for Academic Publications Japan

雑誌

Journal of Nutritional Science and Vitaminology (ISSN:03014800)

巻号頁・発行日

vol.53, no.3, pp.219-224, 2007 (Released:2007-11-27)

参考文献数

46

被引用文献数

17 24

---

Alkaline phosphatase (ALP) hydrolyzes a variety of monophosphate esters into inorganic phosphoric acid and alcohol at a high optimal pH, and is thought to play an important role in phosphate metabolism. Intestinal ALP, located at the brush border of intestinal epithelial cells, is known to be affected by several kinds of nutrients, but little is known about the physiological function of intestinal ALP. Vitamin K is an essential cofactor for the post-translational carboxylation of glutamate residues into gamma-carboxy glutamate (Gla). Recently, novel functions of vitamin K have been clarified, but no data exist on the relation between vitamin K and intestinal ALP. The aim of this study was to examine the effects of both vitamin Ks (K1: phylloquinone, and K2: menaquinone) on ALP activity. Sprague-Dawley rats (6-wk-old) were divided into three groups: a control, phylloquinone (PK: 600 mg/kg diet), or menaquinone-4 (MK-4: 600 mg/kg diet) diet group. After 3 mo of feeding, we measured intestinal ALP activity by dividing it into five segments. In each segment, both PK and MK-4 increased intestinal ALP activity. The levels of intestinal ALP activity in the duodenum and proximal jejunum from the PK group were significantly higher than in the control group (p<0.05). Moreover, the levels of intestinal ALP activity from the proximal jejunum and distal ileum of the intestine in the MK group were significantly higher than in the control group (p<0.05). In this study, we clarified for the first time that both vitamin K1 and K2 as nutritional factors enhance intestinal ALP activity.